Deepanjan Ray
Research Subjects
Deepanjan Ray has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Anoop Velayudhan
Affiliation Indian Council of Medical Research, New Delhi, India
1 shared publication - Bobby Paul
All India Institute of Hygiene and Public Health, Kolkata, India
1 shared publication - Devi Das
Department of Epidemiology, National Institute for Research in Bacterial Infections, Indian Council of Medical Research, Kolkata 700010, West Bengal, India
1 shared publication - Indranil Saha
Department of Epidemiology, ICMR-National Institute for Research in Bacterial Infections, Indian Council of Medical Research, Kolkata, West Bengal, India
1 shared publication - Mihir Bhatta
Department of Clinical Research, National Institute for Research in Bacterial Infections, Indian Council of Medical Research, Kolkata 700010, West Bengal, India
1 shared publication - Saibal Das
Academy of Scientific and Innovative Research (An Institution of National Importance Established by an Act of Parliament) Ghaziabad India
1 shared publication
Latest Publications
- Open Access
- 10 September 2026
- Published by MDPI AG in Healthcare
- Vol. 14 (18) , 2962
Prevalence and Determinants of Never Treatment During Mass Drug Administration for Lymphatic Filariasis: A Systematic Review and Meta-Analysis
Objectives: The term “never treated” refers to individuals who self-report having never ingested tablets during any round of Mass Drug Administration (MDA) against Lymphatic Filariasis (LF). This study estimated the pooled prevalence of never-treated individuals with MDA for LF and identified factors associated with persistent non-treatment. Methods: This systematic review and meta-analysis was registered in PROSPERO [CRD420251270067] and conducted in accordance with the PRISMA 2020 guidelines. Relevant literature was identified by searching databases, i.e., PubMed, Scopus, Cochrane Central, Embase, Web of Science, and Epistemonikos from January 2000 to December 2025, and only studies published in English were included. The AXIS tool was used to assess the study quality. A random-effects model with 95% CI was applied to estimate the pooled prevalence. Subgroup, leave-one-out sensitivity, and meta-regression analyses were conducted to explore the heterogeneity. Results: Eighteen studies including 24,940 individuals showed the pooled prevalence of never treatment during all MDA rounds at 26% (95% CI: 16% to 37%, I2 = 99.7%, 95% prediction interval: 0% to 75%). Exploratory subgroup analysis indicated wide regional and MDA round-specific variations. Meta-regression indicated that publication year did not explain the variability. Common reasons for persistent non-treatment included fear of side effects, limited knowledge, difficulty swallowing the pills, and absence during drug distribution. Conclusions: Persistently never-treated populations may represent an important programmatic barrier to LF elimination. Given the very low certainty of evidence, extreme heterogeneity, and potential publication bias, these estimates should be interpreted cautiously. Future research should ensure broader geographical representation, including both urban and rural areas, and explore structural, behavioural, and socio-cultural determinants to better target high-risk groups.
- 10 September 2026
- Published by MDPI AG in Healthcare
- Vol. 14 (18) , 2962
Open AccessPrevalence and Determinants of Never Treatment During Mass Drug Administration for Lymphatic Filariasis: A Systematic Review and Meta-Analysis
Objectives: The term “never treated” refers to individuals who self-report having never ingested tablets during any round of Mass Drug Administration (MDA) against Lymphatic Filariasis (LF). This study estimated the pooled prevalence of never-treated individuals with MDA for LF and identified factors associated with persistent non-treatment. Methods: This systematic review and meta-analysis was registered in PROSPERO [CRD420251270067] and conducted in accordance with the PRISMA 2020 guidelines. Relevant literature was identified by searching databases, i.e., PubMed, Scopus, Cochrane Central, Embase, Web of Science, and Epistemonikos from January 2000 to December 2025, and only studies published in English were included. The AXIS tool was used to assess the study quality. A random-effects model with 95% CI was applied to estimate the pooled prevalence. Subgroup, leave-one-out sensitivity, and meta-regression analyses were conducted to explore the heterogeneity. Results: Eighteen studies including 24,940 individuals showed the pooled prevalence of never treatment during all MDA rounds at 26% (95% CI: 16% to 37%, I2 = 99.7%, 95% prediction interval: 0% to 75%). Exploratory subgroup analysis indicated wide regional and MDA round-specific variations. Meta-regression indicated that publication year did not explain the variability. Common reasons for persistent non-treatment included fear of side effects, limited knowledge, difficulty swallowing the pills, and absence during drug distribution. Conclusions: Persistently never-treated populations may represent an important programmatic barrier to LF elimination. Given the very low certainty of evidence, extreme heterogeneity, and potential publication bias, these estimates should be interpreted cautiously. Future research should ensure broader geographical representation, including both urban and rural areas, and explore structural, behavioural, and socio-cultural determinants to better target high-risk groups.